Utilico Insights - Jacqueline Broers assesses why Vietnam could be the darling of Asia for investors. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Regulatory News (HEMO)

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.76
Bid: 1.73
Ask: 1.79
Change: 0.00 (0.00%)
Spread: 0.06 (3.468%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.76
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presentation at Cancer Immunotherapy Conference

30 Jan 2019 07:00

RNS Number : 4516O
Hemogenyx Pharmaceuticals PLC
30 January 2019
 

Hemogenyx Pharmaceuticals plc 

("Hemogenyx" or the "Company")

 

Hemogenyx to Present at the 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit' conference

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that its CEO Dr Vladislav Sandler will present at the conference 'Cancer Immunotherapy: Mechanistic Insights to Improve Clinical Benefit'. The conference is taking place in Whistler, Canada from 10 to 14 March 2019 and is organized within the Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/Egxj3V).

 

Dr Sandler's presentation is entitled 'A Novel Anti-FLT3-CD3 Bispecific Antibody for the Treatment of Acute Myeloid Leukemia and Conditioning of Patients for Hematopoietic Stem Cell Transplantation'. The presentation will highlight the fact that, despite numerous advances in understanding the biology and pathogenesis of acute myeloid leukemia (AML), treatment remains unsatisfactory and that relapsed or refractory AML is nearly universally fatal. The presentation will describe the state of development of the Company's CDX antibodies and their potential benefit for the treatment of AML and conditioning of patients for hematopoietic stem cell (HSC) transplantation.

Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/epxTuf) is a nonprofit organization with a 47-year history of convening open, peer-reviewed conferences that connect the scientific community and accelerate life science discovery. Its Scientific Advisory Board is comprised of eminent biomedical scientists whose expertise derives from academia, industry, and the government (https://goo.gl/GtwUjT).

 

 

Enquiries:

 

Hemogenyx Pharmaceuticals plc

www.hemogenyx.com

Dr Vladislav Sandler, Chief Executive Officer & Co-Founder

Via Walbrook PR

Sir Marc Feldmann, Executive Chairman

Northland Capital Partners Limited

Tel: +44 (0)20 3861 6625

Matthew Johnson, Vadim Alexandre

Peterhouse Corporate Finance Limited

Tel: +44 (0)20 7469 0930

Lucy Williams, Duncan Vasey

Walbrook PR (UK Media & Investor Relations)

Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com

Paul McManus

Mob: +44 (0)7980 541 893

US Media enquiries

Lowell Goodman

Tel: +1 (323) 646-3249 or lowell@corbomitecomms.com

 

 

About Hemogenyx Pharmaceuticals plc

 

Hemogenyx Pharmaceuticals plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned US operating subsidiary, Hemogenyx LLC, located in New York City at its state-of-the-art research facility ("Hemogenyx").

 

Hemogenyx is a pre-clinical stage biopharmaceutical group developing new medicines and treatments to bring the curative power of bone marrow transplantation to a greater number of patients suffering from otherwise incurable life-threatening diseases. Hemogenyx is developing two distinct and complementary products, as well as a platform technology that it uses as an engine for novel product development.

 

For more than 50 years, bone marrow transplantation has been used to save the lives of patients suffering from blood diseases. The risks of toxicity and death that are associated with bone marrow transplantation, however, have meant that the procedure is restricted to use only as a last resort. Hemogenyx's technology has the potential to enable many more patients suffering from devastating blood diseases such as leukemia and lymphoma, as well as severe autoimmune diseases such as multiple sclerosis, aplastic anemia and systemic lupus erythematosus (Lupus), to benefit from bone marrow transplantation.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCMMGZMVLGGLZM
Date   Source Headline
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T
9th May 20237:00 amRNSSubmission of IND for HEMO-CAR-T
28th Apr 202310:05 amRNSEquity Incentive Pool Increase and Option Grant
28th Apr 20237:00 amRNSFinal Results for the Year Ended 31 December 2022
23rd Mar 20231:32 pmRNSHEMO-CAR-T Analytical Release Tests Completed
28th Feb 20237:00 amRNSTotal Voting Rights
7th Feb 20232:30 pmRNSAdmission of Shares to Official List
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSPlacing to Raise £4,056,250
23rd Jan 20237:00 amRNSHEMO-CAR-T 3rd Process Qualification Run Completed
16th Jan 20234:40 pmRNSSecond Price Monitoring Extn
16th Jan 20234:35 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
12th Jan 20234:40 pmRNSSecond Price Monitoring Extn
12th Jan 20234:35 pmRNSPrice Monitoring Extension
12th Jan 20232:05 pmRNSSecond Price Monitoring Extn
12th Jan 20232:00 pmRNSPrice Monitoring Extension
10th Jan 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20239:05 amRNSSecond Price Monitoring Extn
9th Jan 20239:00 amRNSPrice Monitoring Extension
9th Jan 20237:00 amRNSSingle CBR Can Treat Multiple Viruses
5th Jan 20234:40 pmRNSSecond Price Monitoring Extn
5th Jan 20234:35 pmRNSPrice Monitoring Extension
5th Jan 202311:05 amRNSSecond Price Monitoring Extn
5th Jan 202311:00 amRNSPrice Monitoring Extension
4th Jan 20237:00 amRNSHEMO-CAR-T Process Qualification Run Completed
12th Dec 20227:00 amRNSHEMO-CAR-T First PQ Run Completed
18th Nov 20223:19 pmRNSHEMO-CAR-T Process Development Runs Completed
18th Nov 202211:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.